Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF350 antisense RNA 1 (ZNF350-AS1) is a long non-coding RNA (lncRNA) gene located at chromosome 19q13.41 that does not encode a protein but instead regulates gene expression and chromatin state, often by acting as an antisense regulator for the nearby ZNF350 gene[1][4][5]. ZNF350-AS1 is reported under several aliases, notably HCCAT3, and has been implicated in the progression of multiple cancers, including hepatocellular carcinoma where its upregulation may facilitate tumor growth[3][4]. Its mechanisms include recruiting transcription factors, influencing enhancer activity, regulating alternative splicing, and potentially participating in RNA editing events[1][4]. While evidence suggests a role as a biomarker for some cancer types, there are currently no known drug interactions or targeted therapeutic agents, nor is it categorized as a therapeutic target such as a receptor or enzyme[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZNF350 antisense RNA 1 (ZNF350-AS1).